Studies have confirmed that BET inhibitors and cytarabine can suppress SPP1 transcription, while Entrectinib directly binds to SPP1 and reduces its expression (77–79), resulting in synergistic anti-tumor effects. The gene discussed is SPP1; the disease is neoplasm.